RE:RE:Keytruda resistance shown as a monotherapy in anal cancer
Comment by
Noteableon Jan 29, 2024 1:57pm 
116 Views
Post# 35850918
RE:Keytruda resistance shown as a monotherapy in anal cancer
Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response
SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International
Merck is now favorably looking at combining other I/O agents, like ONCY's pelareorep, to enhance the effectiveness of Keytuda.
RE:Keytruda resistance shown as a monotherapy in anal cancer
Convetsely ... Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response
SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, taking place in Rome, Italy.